Assessment of the burden of outpatient clinic and MRI-guided needle muscle biopsies as reported by patients with facioscapulohumeral muscular dystrophy

[1]  L. Ross,et al.  Muscle biopsy practices in the evaluation of neuromuscular disease: A systematic literature review , 2023, Neuropathology and applied neurobiology.

[2]  L. Ronco,et al.  Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI , 2022, Neurology.

[3]  S. Tapscott,et al.  Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers , 2022, Scientific Reports.

[4]  L. Ronco,et al.  Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement , 2021, British journal of clinical pharmacology.

[5]  M. Signorelli,et al.  Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay , 2021, Scientific Reports.

[6]  A. Heerschap,et al.  Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy , 2020, Muscle & nerve.

[7]  F. Muntoni,et al.  Muscle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ and caregivers’ perspective , 2019, Neuromuscular Disorders.

[8]  Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 , 2019, Case Medical Research.

[9]  J. Fütterer,et al.  MRI-Guided Biopsy as a Tool for Diagnosis and Research of Muscle Disorders , 2018, Journal of neuromuscular diseases.

[10]  B. Ekblom,et al.  The muscle biopsy technique. Historical and methodological considerations , 2017, Scandinavian journal of medicine & science in sports.

[11]  B. Engelen,et al.  225th ENMC international workshop: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands , 2017, Neuromuscular Disorders.

[12]  C. Horlings,et al.  What's in a name? The clinical features of facioscapulohumeral muscular dystrophy , 2016, Practical Neurology.

[13]  A. Ludolph,et al.  Differences in pain perception during open muscle biopsy and Bergstroem needle muscle biopsy , 2014, Journal of pain research.

[14]  A. Verbeek,et al.  Population-based incidence and prevalence of facioscapulohumeral dystrophy , 2014, Neurology.

[15]  Daniel G. Miller,et al.  Longitudinal features of stir bright signal in FSHD1 , 2014, Muscle & nerve.

[16]  G. Meola,et al.  Muscle biopsy , 2011, Journal of Neurology.

[17]  Daniel G. Miller,et al.  A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.

[18]  B. Engelen,et al.  171st ENMC International Workshop: Standards of care and management of facioscapulohumeral muscular dystrophy , 2010, Neuromuscular Disorders.

[19]  R. Frants,et al.  Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. , 2008, Mutation research.

[20]  F. Maltais,et al.  Skeletal muscle microbiopsy: a validation study of a minimally invasive technique , 2005, European Respiratory Journal.

[21]  M. Magistris,et al.  Needle muscle biopsy in the investigation of neuromuscular disorders , 1998, Muscle & nerve.